1887

Abstract

Sexual history is an established risk determinant for cervical neoplasia. It is not clear if human papillomavirus (HPV) exposure entirely explains the sexual behaviour-related risk or if other sexually transmitted agents may act as cofactors for HPV in carcinogenesis. The aim of this study was to elucidate whether HPV exposure or HPV persistence explains the sexual history-related risk of high-grade cervical intraepithelial neoplasia (CIN) using a population-based case-control study of most of the 254 women referred to colposcopy in the Vasterbotten county in Sweden because of an abnormal cervical smear during October 1993 to December 1995 and 320 age-matched women from the general population. The women were interviewed for sexual history and tested for presence of serum antibodies to HPV-16, -18 and -33 as well as for presence of HPV DNA in cervical brush samples. HPV-16, -18 and -33 seropositivity was specific for the corresponding type of HPV DNA, dependent on the lifetime sexual history and associated with a two- to threefold increased risk of CIN 3. There was no sexual history-related risk of CIN among HPV-seropositive women and adjustment for HPV DNA presence explained the sexual history-related risk of CIN. In conclusion, HPV exposure appeared to explain the sexual history-related risk of high-grade CIN.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-80-2-391
1999-02-01
2022-05-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/80/2/0800391a.html?itemId=/content/journal/jgv/10.1099/0022-1317-80-2-391&mimeType=html&fmt=ahah

References

  1. Af Geijersstam V., Kibur M., Wang Z., Koskela P., Pukkala E., Schiller J. T., Lehtinen M., Dillner J. 1998; Stability serum antibody levels to human papillomavirus type 16. Journal of Infectious Diseases 177:1710–1714
    [Google Scholar]
  2. Andersson-Ellstrom A., Dillner J., Hagmar B., Schiller J., Sapp M., Forssman L., Milsom I. 1996; Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sexually Transmitted Diseases 23:234–238
    [Google Scholar]
  3. Bauer H. M., Ting Y., Greer C., Chambers J., Tashiro C., Chimera J., Reingold A., Manos M. M. 1991; Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 265:472–478
    [Google Scholar]
  4. Becker T., Wheeler C. M., McGough N. S., Parmenter C., Jordan S. W., Stidley C. A., McPherson S., Dorin M. H. 1994; Sexually transmitted diseases and other risk factors for cervical dysplasia among southwestern Hispanic and non-Hispanic white women. JAMA 271:1181–1188
    [Google Scholar]
  5. Brinton L. A., Hamman R. F., Huggins G. R., Lehman H. F., Levine R. S., Mallin K., Fraumeni J. F. 1987; Sexual and reproductive risk factors for invasive squamous cell cervical cancer. Journal of the National Cancer Institute 79:23–30
    [Google Scholar]
  6. Carter J. J., Koutsky L. A., Wipf G. C., Christensen N. D., Lee S. K., Kuypers J., Kiviat N., Galloway D. A. 1996; The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. Journal of Infectious Diseases 174:927–936
    [Google Scholar]
  7. Chua K.-L., Wiklund F., Lenner P., Ångström T., Hallmans G., Bergman F., Sapp M., Schiller J., Wadell G., Hjerpe A., Dillner J. 1996; A prospective study on the risk of cervical intra-epithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPV DNA in cervical smears. International Journal of Cancer 68:54–59
    [Google Scholar]
  8. de Gruijl T. D., Bontkes H. J., Walboomers J. M. M., Schiller J. T., Stukart M. J., Groot B. S., Chabaud M. M., Remmink A. J., Verheijen R. H., Helmerhorst T. J., Meijer C. J., Scheper R. J. 1997; Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. Journal of the National Cancer Institute 89:630–638
    [Google Scholar]
  9. de Sanjosé S., Munoz N., Bosch F. X., Reimann K., Pedersen N. S., Orfila J., Ascunce N., Gonzalez L. C., Tafur L., Gilli M., Lette I., Viladiu P., Tormo M. J., Moreo P., Shah K., Wahren B. 1994; Sexually transmitted agents and cervical neoplasia in Colombia and Spain. International Journal of Cancer 65:358–363
    [Google Scholar]
  10. Dillner J., Lenner P., Lehtinen M., Eklund C., Heino P., Wiklund F., Hallmans G., Stendahl U. 1994; A population-based sero-epidemiological study of cervical cancer. Cancer Research 54:134–141
    [Google Scholar]
  11. Dillner J., Kallings I., Brihmer C., Sikström B., Koskela P., Lehtinen M., Schiller J. T., Sapp M., Mårdh P. A. 1996; Seropositivity to human papillomavirus types 16, 18 or 33 capsids and to Chlamydia trachomatis are markers of sexual behaviour. Journal of Infectious Diseases 173:1394–1398
    [Google Scholar]
  12. Dillner J., Lehtinen M., Björge T., Luostarinen T., Youngman L., Jellum E., Koskela P., Gislefoss R. E., Hallmans G., Paavonen J., Sapp M., Schiller J. T., Hakulinen T., Thoresen S., Hakama M. 1996; Prospective seroepidemiological study of human papillomavirus infection as risk factor for invasive cervical cancer. Journal of the National Cancer Institute 89:1293–1299
    [Google Scholar]
  13. Dillner J., Knekt P., Boman J., Lehtinen M., Af Geijersstam V., Sapp M., Schiller J., Maatela J., Aromaa A. 1998; Seroepidemiological association between human papillomavirus infection and risk of prostate cancer. International Journal of Cancer 75:564–567
    [Google Scholar]
  14. Evander M., Wadell G. 1991; A general primer for amplification and detection of genital human papillomavirus types. Journal of Virological Methods 31:239–250
    [Google Scholar]
  15. Evander M., Edlund K., Boden E., Gustavsson Å., Jonsson M., Karlsson R., Rylander E., Wadell G. 1992; Comparison of a one-step and a two-step polymerase chain reaction with degenerate general primers in a population-based study of human papillomavirus infection in young Swedish women. Journal of Clinical Microbiology 30:987–992
    [Google Scholar]
  16. Evander M., Edlund K., Gustafsson A., Jonsson M., Karlsson R., Rylander E., Wadell G. 1995; Human papillomavirus infection is transient in young women: a population-based cohort study. Journal of Infectious Diseases 171:1026–1030
    [Google Scholar]
  17. Franco E.L. 1991; The sexually transmitted disease model for cervical cancer: incoherent epidemiologic findings and the role of misclassification of human papillomavirus infection. Epidemiology 2:98–106
    [Google Scholar]
  18. Hakama M., Lehtinen M., Knekt P., Aromaa A., Leinikki P., Miettinen A., Paavonen J., Peto R., Teppo L. 1993; Serum antibodies and subsequent cervical neoplasms: a prospective study with 12 years of follow-up. American Journal of Epidemiology 137:166–170
    [Google Scholar]
  19. Heino P., Skyldberg B., Lehtinen M., Rantala I., Hagmar B., Kreider J. W., Kirnbauer R., Dillner J. 1995; Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. Journal of General Virology 76:1141–1153
    [Google Scholar]
  20. Hildesheim A., Mann V., Brinton L. A., Szklo M., Reeves W. C., Rawls W. E. 1993; Herpes simplex virus type 2: a possible interaction with human papillomavirus types 16/18 and the development of invasive cervical cancer. American Journal of Epidemiology 137:166–170
    [Google Scholar]
  21. Hildesheim A., Schiffman M. H., Gravitt P. E., Glass A. G., Greer C. E., Zhang T., Scott D. R., Rush B. B., Lawler P., Sherman M. E. 1994; Persistence of type-specific human papillomavirus infection among cytologically normal women. Journal of Infectious Diseases 169:235–240
    [Google Scholar]
  22. Ho G. Y. F., Bierman R., Beardsley L., Chang C. J., Burk R. D. 1996; Natural history of cervicovaginal papillomavirus infection in young women. New England Journal of Medicine 338:423–428
    [Google Scholar]
  23. Kirnbauer R., Hubbert N. L., Wheeler C. M., Becker T. M., Lowy D.R., Schiller J. T. 1994; A virus-like particle ELISA detects serum antibodies in a majority of women infected with human papillomavirus type 16. Journal of the National Cancer Institute 86:4904–4909
    [Google Scholar]
  24. Kjellberg L., Wiklund F., Sjoberg I., Wadell G., Angstrom T., Dillner J., Mahlck C. G. 1998; A population-based study of HPV DNA testing for predicting cervical intraepithelial neoplasia. American Journal of Obstetrics and Gynecology (in press)
    [Google Scholar]
  25. Koss L. G. (editor) 1979 Diagnostic Cytology and its Histologic Basis 3rd edn Philadelphia: Lippincott;
    [Google Scholar]
  26. Manos M. M., Ting Y., Wright D. K., Lewis A. J., Broker T. R., Wollinsky S. M. 1989; Use of polymerase chain reaction amplification for the detection of genital human papillomavirus. Cancer Cells 7:209–214
    [Google Scholar]
  27. Melkert P. W., Hopman E., Van Den Brule A. J., Risse E. K., Van Diest P. J., Bleker O. P., Helmerhorst T., Schipper M. E., Meijer C. J., Walboomers J. M. 1993; Prevalence of HPV in cyto-morphologically normal smears, as determined by the polymerase chain reaction, is age-dependent. International Journal of Cancer 53:919–923
    [Google Scholar]
  28. Munoz N., Bosch F. X., de Sanjose S., Vergara A., del Moral A., Munoz M. T., Tafur L., Gili M., Izarzugaza I., Viladiu P. and 7 others 1993; Risk factors for cervical intraepithelial neoplasia grade III/ carcinoma in situ in Spain and Colombia. Cancer Epidemiology, Biomarkers and Prevention 2:423–431
    [Google Scholar]
  29. Olsen A. O., Dillner J., Gjoen K., Magnus P. 1997; Seropositivity against HPV 16 capsids: a better marker of past sexual behavior than presence of HPV DNA. Genitourinary Medicine 73:131–135
    [Google Scholar]
  30. Parkin D. M., Laara E., Muir C. S. 1988; Estimates of the worldwide frequency of 16 major cancers in 1980. International Journal of Cancer 41:184–197
    [Google Scholar]
  31. Schiffman M. H. 1995; Epidemiology of human papillomaviruses. Dermatology Clinics 13:561–574
    [Google Scholar]
  32. Schiffman M. H., Bauer H. M., Hoover R. N., Glass A. G., Cadell D. M., Rush B. B., Scott D. R., Sherman M. E., Kurman R. J., Wacholder S., Stanton C. K., Manos M. M. 1993; Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. Journal of the National Cancer Institute 85:958–964
    [Google Scholar]
  33. Slattery M. L., Overall J. C., Abbott T. M., French T. K., Robinson L. M., Gardner J. 1989; Sexual activity, contraception, genital infections, and cervical cancer: support for a sexually transmitted disease hypothesis. American Journal of Epidemiology 130:248–258
    [Google Scholar]
  34. Snijders P. J. F., van den Brule A. J. C., Schrijnemakers H. F. J., Snow G., Meijer C. J. L. M., Walboomers J. M. M. 1990; The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. Journal of General Virology 71:173–181
    [Google Scholar]
  35. Stone K., Zaidi A., Rosero-Bixby L., Oberle M. W., Reynolds G., Larsen S., Nahmias A. J., Lee F., Schachter J., Guinan M. E. 1995; Sexual behaviour, sexually transmitted diseases, and risk of cervical cancer. Epidemiology 6:409–414
    [Google Scholar]
  36. Strickler H. D., Schiffman M. H., Eklund C., Glass A. G., Scott D. R., Sherman M. E., Wacholder S., Kurman R. J., Manos M. M., Schiller J.T., Dillner J. 1997; Evidence for at least two distinct groups of humoral immune reactions to papillomavirus antigens in women with squamous intraepithelial lesions. Cancer Epidemiology, Biomarkers and Prevention 6:183–188
    [Google Scholar]
  37. Wideroff L., Schiffman M. H., Nonnenmacher B., Hubbert N., Kirnbauer R., Greer C. E., Lowy D., Lorincz A. T., Manos M. M., Glass A. G., Scott D. R., Sherman M. E., Kurman R. J., Buckland J., Tarone R. E., Schiller J. 1995; Evaluation of seroreactivity to human papillomavirus type 16 virus-like particle in an incident case-control study of cervical neoplasia. Journal of Infectious Diseases 172:1425–1430
    [Google Scholar]
  38. Wideroff L., Schiffman M. H., Hoover R., Tarone R. E., Nonnen-macher B., Hubbert N., Kirnbauer R., Greer C. E., Lorincz A. T., Manos M. M., Glass A. G., Scott D. R., Sherman M. E., Buckland J., Lowy D., Schiller J. 1996; Epidemiologic determinants of sero-reactivity to human papillomavirus type 16 virus-like particles in cervical HPV16 DNA-positive and negative women. Journal of Infectious Diseases 174:937–943
    [Google Scholar]
  39. Wikström A., van Doornum G. J. J., Quint W. G. V., Schiller J. T., Dillner J. 1995; Identification of human papillomavirus sero-conversions. Journal of General Virology 76:529–539
    [Google Scholar]
  40. Viscidi R. P., Kotloff K. L., Clayman B., Russ K., Shapiro S., Shah K.V. 1997; Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clinical and Diagnostic Laboratory Immunology 4:122–126
    [Google Scholar]
  41. Yap E., Ho T. H., Chan Y. C., Thong T. W., Ng G. C., Ho L. C., Singh M. 1995; Serum antibodies to Trichomonas vaginalis in invasive cervical cancer patients. Genitourinary Medicine 71:402–404
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-80-2-391
Loading
/content/journal/jgv/10.1099/0022-1317-80-2-391
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error